Mhawech-Fauceglia Paulette, Dulguerov Pavel, Beck Amy, Bonet Marta, Allal Abdelkarim S
Department of Pathology, Geneva University Hospital, Geneva, Switzerland.
J Clin Pathol. 2007 Feb;60(2):185-9. doi: 10.1136/jcp.2006.036624. Epub 2006 May 12.
Prognostic factors in predicting outcomes in patients with head and neck squamous-cell carcinoma (HNSCC) are limited to the clinical-pathological parameters, including lymph node metastasis, location, grade and stage of the disease.
To determine whether the expression of these proteins has a value in predicting patient outcome.
Ezrin, maspin and nm23-H1 immunohistochemistry in tissue samples of 120 patients with HNSCC were evaluated using the microarray technique.
In determining the association among each of the three proteins and the clinical-pathological parameters, low maspin expression was the only one found to be significantly associated with high tumour grade (p = 0.007); all others showed no significant associations. In univariate analysis, patients with tumours expressing high ezrin had a shorter disease-free survival (DFS) of 51% than those with low ezrin expression (DFS 84%; p = 0.08). In multivariate analysis, tumours with the combination of loss of maspin and low histological grade had longer DFS (83%) compared with those with high maspin and high histological grade (DFS 42%; p = 0.08).
Our study is the first to determine the value of ezrin and maspin in HNSCC in a large series of patients with long follow-up. Ezrin and maspin seem to have a potential prognostic value in patients with HNSCC but results should be confirmed with further studies.
预测头颈部鳞状细胞癌(HNSCC)患者预后的因素仅限于临床病理参数,包括淋巴结转移、疾病部位、分级和分期。
确定这些蛋白的表达在预测患者预后方面是否具有价值。
采用微阵列技术评估120例HNSCC患者组织样本中的埃兹蛋白、组织蛋白酶抑制因子和nm23-H1免疫组化情况。
在确定这三种蛋白各自与临床病理参数之间的关联时,发现组织蛋白酶抑制因子低表达是唯一与高肿瘤分级显著相关的因素(p = 0.007);其他均无显著关联。单因素分析显示,埃兹蛋白高表达的肿瘤患者无病生存期(DFS)为51%,低于埃兹蛋白低表达患者(DFS 84%;p = 0.08)。多因素分析显示,组织蛋白酶抑制因子缺失与低组织学分级组合的肿瘤患者DFS较长(83%),而组织蛋白酶抑制因子高表达与高组织学分级组合的患者DFS为42%(p = 0.08)。
我们的研究首次在大量长期随访的患者中确定了埃兹蛋白和组织蛋白酶抑制因子在HNSCC中的价值。埃兹蛋白和组织蛋白酶抑制因子似乎在HNSCC患者中具有潜在的预后价值,但结果应通过进一步研究加以证实。